Almirall and Forest Laboratories have announced that a Phase 3 study of their aclidinium bromide DPI for the treatment of COPD produced significant improvement from baseline in FEV1 at clinical doses but underperformed when compared to placebo. Another Phase 3 double-blind study is still underway, and Forest Lab’s President Lawrence S. Olanoff expressed confidence that the results, which are expected in the first quarter of 2011, will be more in line with the promising results from previous studies. Read the company’s press release.
Disappointing Phase 3 results for aclidinium bromide
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
